Patents by Inventor Justin M. Scheer

Justin M. Scheer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific and tetravalent CD137 and FAP molecules for the treatment of cancer
    Patent number: 12146000
    Abstract: This invention relates to binding molecules that bind specifically to CD137 and FAP and their use in medicine, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Grant
    Filed: May 18, 2021
    Date of Patent: November 19, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Eric Borges, Pankaj Gupta, Daniel Christopher Rowe, Justin M. Scheer, Abdallah Souabni, Inigo Tirapu, Joseph Ronald Tumang
  • Bispecific anti-VEGF and anti-TrkB binding molecules for the treatment of eye diseases
    Patent number: 12110335
    Abstract: This invention relates to binding molecules that bind specifically Vascular Endothelial Growth Factor (VEGF) and Tropomyosin receptor kinase B (TrkB) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: October 8, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Michael Benz, Remko Alexander Bakker, Holger Fuchs, Fei Han, Sandeep Kumar, Sarah Low, Justin M. Scheer, Leo Thomas
  • Bispecific and tetravalent CD137 and FAP molecules for the treatment of cancer
    Patent number: 11999800
    Abstract: This invention relates to binding molecules that bind specifically to CD137 and FAP and their use in medicine, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Grant
    Filed: May 18, 2021
    Date of Patent: June 4, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Eric Borges, Pankaj Gupta, Daniel Christopher Rowe, Justin M. Scheer, Abdallah Souabni, Inigo Tirapu, Joseph Ronald Tumang
  • FC Variants and Methods for Their Production
    Publication number: 20240158513
    Abstract: Described herein are Fc variants and methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins). Heteromultimeric proteins may be capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.
    Type: Application
    Filed: January 16, 2024
    Publication date: May 16, 2024
    Applicant: Genentech, Inc.
    Inventors: J. Michael ELLIOTT, Justin M. Scheer
  • MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT
    Publication number: 20230340130
    Abstract: The present invention relates to novel B7H6/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: June 20, 2023
    Publication date: October 26, 2023
    Inventors: Susanne HIPP, Paul ADAM, Michael DZIEGELEWSKI, Rajukumar GANESAN, Phillip Nicholas GORMAN, Pankaj GUPTA, Priyanka GUPTA, Marcio LASARO, Justin M. SCHEER, Vladimir H. VOYNOV
  • Multi-specific binding proteins for cancer treatment
    Patent number: 11732045
    Abstract: The present invention relates to novel B7H6/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: August 22, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Susanne Hipp, Paul Adam, Michael Dziegelewski, Rajkumar Ganesan, Philip Nicholas Gorman, Pankaj Gupta, Priyanka Gupta, Marcio Lasaro, Justin M. Scheer, Vladimir H. Voynov
  • AGONISTIC TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES
    Publication number: 20220119536
    Abstract: The invention relates to agonistic TrkB binding molecules, methods for improving agonistic TrkB binders, their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.
    Type: Application
    Filed: October 20, 2021
    Publication date: April 21, 2022
    Inventors: Peter Michael BENZ, Remko Alexander BAKKER, Holger FUCHS, Fei HAN, Sandeep KUMAR, Sarah LOW, Justin M. SCHEER, Leo THOMAS
  • BISPECIFIC ANTI-VEGF AND ANTI-TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES
    Publication number: 20220119535
    Abstract: This invention relates to binding molecules that bind specifically Vascular Endothelial Growth Factor (VEGF) and Tropomyosin receptor kinase B (TrkB) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.
    Type: Application
    Filed: October 20, 2021
    Publication date: April 21, 2022
    Inventors: Peter Michael BENZ, Remko Alexander BAKKER, Holger FUCHS, Fei HAN, Sandeep KUMAR, Sarah LOW, Justin M. SCHEER, Leo THOMAS
  • BINDING MOLECULES FOR THE TREATMENT OF CANCER
    Publication number: 20210363273
    Abstract: This invention relates to binding molecules that bind specifically to CD137 and FAP and their use in medicine, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Application
    Filed: May 18, 2021
    Publication date: November 25, 2021
    Inventors: Eric BORGES, Pankaj GUPTA, Daniel Christopher ROWE, Justin M. SCHEER, Abdallah SOUABNI, Inigo TIRAPU, Joseph Ronald TUMANG
  • MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT
    Publication number: 20210107983
    Abstract: The present invention relates to novel B7H6/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: October 1, 2020
    Publication date: April 15, 2021
    Inventors: Susanne HIPP, Paul ADAM, Michael DZIEGELEWSKI, Rajkumar GANESAN, Philip Nicholas GORMAN, Pankaj GUPTA, Priyanka GUPTA, Marcio LASARO, Justin M. SCHEER, Vladimir M. VOYNOV
  • Anti-factor D antibody variant conjugates and uses thereof
    Patent number: 10961313
    Abstract: The disclosure relates to antibody-polymer conjugates comprising one or more anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: March 30, 2021
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Robert F. Kelley, Justin M. Scheer, Whitney Shatz, Devin Tesar, Menno van Lookeren Campagne
  • Anti-factor D antibody variant conjugates and uses thereof
    Patent number: 10654932
    Abstract: The disclosure relates to antibody-polymer conjugates comprising one or more anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: May 19, 2020
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Robert F. Kelley, Justin M. Scheer, Whitney Shatz, Devin Tesar, Menno van Lookeren Campagne
  • ANTI-FACTOR D ANTIBODY VARIANT CONJUGATES AND USES THEREOF
    Publication number: 20200115462
    Abstract: The disclosure relates to antibody-polymer conjugates comprising one or more anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
    Type: Application
    Filed: December 30, 2019
    Publication date: April 16, 2020
    Inventors: Philip E. Hass, Robert F. Kelley, Justin M. Scheer, Whitney Shatz, Devin Tesar, Menno van Lookeren Campagne
  • Anti-factor D antibodies and conjugates
    Patent number: 10407510
    Abstract: The invention provides anti-Factor D antibodies and conjugates and methods of using the same.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: September 10, 2019
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Whitney Shatz, Devin Tesar, Justin M. Scheer, Michelle Dion
  • Anti-factor D antibodies
    Patent number: 10179821
    Abstract: The invention relates to anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: January 15, 2019
    Assignee: GENENTECH, INC.
    Inventors: Robert F Kelley, Menno van Lookeren Campagne, Justin M Scheer, Philip E Hass, Devin Tesar
  • ANTI-FACTOR D ANTIBODIES AND CONJUGATES
    Publication number: 20170145112
    Abstract: The invention provides anti-Factor D antibodies and conjugates and methods of using the same.
    Type: Application
    Filed: October 27, 2016
    Publication date: May 25, 2017
    Applicant: GENENTECH, INC.
    Inventors: Robert F. Kelley, Whitney Shatz, Devin Tesar, Justin M. Scheer, Michelle Dion
  • ANTI-FACTOR D ANTIBODY VARIANT CONJUGATES AND USES THEREOF
    Publication number: 20170143843
    Abstract: The disclosure relates to antibody-polymer conjugates comprising one or more anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
    Type: Application
    Filed: October 27, 2016
    Publication date: May 25, 2017
    Inventors: Philip E. Hass, Robert F. Kelley, Justin M. Scheer, Whitney Shatz, Devin Tesar, Menno van Lookeren Campagne
  • Anti-Factor D Antibody Variants and Uses Thereof
    Publication number: 20160017052
    Abstract: The invention relates to anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
    Type: Application
    Filed: April 30, 2015
    Publication date: January 21, 2016
    Applicant: GENENTECH, INC.
    Inventors: Robert F. Kelley, Menno van Lookeren Campagne, Justin M. Scheer, Philip E. Hass, Devin Tesar